3Q19 GAAP HCV sales were $674M, but the actual product sales of GILD’s three HCV regimens were $703M; the “missing” $29M in the GAAP total was due to a statutory clawback in the EU.
The $703M figure was -8% relative to the adjusted 2Q19 figure of $762M (excluding the $80M true-up reported in 2Q19 as described in #msg-150227808).
Market Data 
Markets 
AI
